



HAL
open science

Developing a set of patient-centered outcomes for routine use in endometriosis: An international Delphi study

Alba Nicolas-Boluda, Enora Le Roux, Arounie Tavenet, Jerome Bouaziz, Paolo Vercellini, Pamela Stratton, Arnaud Fauconnier

► To cite this version:

Alba Nicolas-Boluda, Enora Le Roux, Arounie Tavenet, Jerome Bouaziz, Paolo Vercellini, et al.. Developing a set of patient-centered outcomes for routine use in endometriosis: An international Delphi study. *Acta Obstetricia et Gynecologica Scandinavica*, 2024, 103 (1), pp.138-152. 10.1111/aogs.14694 . hal-04566140

HAL Id: hal-04566140

<https://hal.science/hal-04566140v1>

Submitted on 31 May 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.







L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

ORIGINAL RESEARCH ARTICLE

Developing a set of patient-centered outcomes for routine use in endometriosis: An international Delphi study

Alba Nicolas-Boluda^{1,2}  | Enora Le Roux^{3,4}  | Arounie Tavenet⁵ | Jerome Bouaziz¹  | Paolo Vercellini^{6,7}  | Pamela Stratton⁸  | Arnaud Fauconnier^{9,10} 

¹One Clinic, Paris, France

²European Association of Value-Based Health Care, Brussels, Belgium

³Clinical Epidemiology Unit, Hôpital Universitaire Robert Debré, AP-HP Nord-Université de Paris, Inserm, CIC 1426, Paris, France

⁴ECEVE UMR 1123, Université de Paris, Inserm, Paris, France

⁵EndoFrance, Dagneux, France

⁶Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

⁷Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

⁸Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA

⁹Research Unit 7285 Clinical Risks and Safety in Women's Health and Perinatal Health (RISCQ), UVSQ, Université Paris-Saclay, Montigny-le-Bretonneux, France

¹⁰Gynecology and Obstetrics Department, Centre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Poissy, France

Correspondence

Alba Nicolas-Boluda, One Clinic, 45 rue Pierre Charron, 75008, Paris, France.
Email: alba.nicolas-boluda@one.fr

Abstract

Introduction: There is large variation in individual patient care for endometriosis. A uniform approach to measure outcomes could be incorporated into routine clinical practice to personalize and monitor treatments and potentially improve the quality of care. The aim of this study is to identify a group of patient-centered outcomes for use in routine endometriosis care which are relevant to all patient profiles.

Material and Methods: By means of a modified two-round Delphi study with international representation including healthcare professionals, researchers and patient representatives (51 participants, 16 countries) we developed a set of patient-centered measurements. The participants evaluated 47 Patient Reported Outcome Measures (PROMs) and 30 Clinician Reported Outcome Measures (CROMs) regarding their feasibility and relevance for their use in routine endometriosis care. After the two rounds of quotation, meetings of the experts were convened to participate in a final discussion to finalize the consensus of the final set of included measures.

Results: The final set of patient-centered outcomes includes six PROMs (measuring symptomatic impact, pain, work productivity and quality of life) and 10 CROMs (measuring clinical, imaging and surgical indicators). A supplementary list of outcomes was added to include important dimensions that were considered essential by the expert panel but are not relevant to all patients. In addition the need for development of specific tools (PROMs) measuring the psychological impact and the impact in sexual activity of endometriosis was highlighted.

Conclusions: We have developed a set of patient-centered outcomes measures in endometriosis care. The selected outcomes comprise the common features for all patients suffering from endometriosis. adapted for use in routine practice. The list of outcomes has been adapted for use in routine practice from which clinicians can chose, depending on their needs.

Abbreviations: PROM, Patient Reported Outcome Measure; CROM, Clinician Reported Outcome Measure; MRI, magnetic resonance imaging.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Acta Obstetrica et Gynecologica Scandinavica* published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

KEYWORDS

clinician reported outcome measures, endometriosis, patient reported outcome measures, value-based health care

1 | INTRODUCTION

Endometriosis is a disorder which is characterized by presence of endometrium-like tissue outside the uterus that may impact the reproductive and general health of women during the course of their life.¹ Epidemiological studies show that the worldwide prevalence of endometriosis is around 10% in women of reproductive age.² Multiple symptoms are associated with endometriosis, including severe dysmenorrhea, non-menstrual pelvic pain, dyspareunia, intestinal or urinary symptoms and infertility. The heterogeneity of the symptomatology together with the multiplicity of therapeutic approaches to manage endometriosis-associated symptoms complicate clinical management. As with other chronic pain conditions, endometriosis-related pain often affects a woman's ability to function and her relationships, and can lead to mental health conditions such as depression. Overall, endometriosis can severely impact a patient's quality of life.¹

Incorporating in routine clinical practice a consistent approach to measure outcomes that matter to patients with endometriosis would enable providers to personalize and monitor treatment effects. Measuring outcomes (ie symptoms, quality of life) that are important to patients will be used as indicators to determine the most relevant therapeutic strategy. Outcome measures include both patient symptoms and quality of life using Patient Reported Outcomes Measurement^{3,4} and medical observations, Clinician Reported Outcomes Measurement (CROMs).⁵

Outcome measurements have been extensively used as research tools in clinical trials and have been shown to produce reliable and consistent results across different types of populations to measure treatment effect and satisfaction.⁶ On the other hand, projects like the one led by the World Endometriosis Research Foundation – the Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHeCt) – aim to standardize the collection of minimal clinical information in endometriosis research⁷⁻¹⁰ and facilitate worldwide research. Importantly, in a pure research context, data collection may not in itself offer direct benefit to the individual patient, as this information is not intended for use to modify the patients' care at a particular visit. Moreover, the collection of data is not underpinned by constraints of time or human resources. On the other hand, routine care can be enhanced by using metrics to improve communication between the patient and physician and can therefore be used as shared decision-making tools¹¹ and to increase patient empowerment. The use of patient-reported metrics (ie PROMs) and the fact that they are taken into consideration by the physician will improve patients' awareness, understanding of their pathology and participation in their healthcare pathway.³ Studies have shown that the use of

Key message

We have developed a comprehensive set of patient-centered outcomes measures in endometriosis care that account for clinical variability. These outcomes capture the common features for all endometriosis patients and are suitable for implementation in routine care.

PROMs in routine clinical care improves clinical outcome, enabling patients to measure, report and share the responsibility for the management of their condition.³

The aim of the present study was therefore to identify patient- and clinician-important PROMs and CROMs for use in routine endometriosis care which are relevant to any patient: those with either pain or infertility and clinical or imaging elements suggestive of endometriosis before its diagnosis; also, those with complex or severe disease. For that purpose we conducted a modified Delphi consensus process with an international multidisciplinary group of experts and patients in endometriosis including healthcare professionals (gynecologists, surgeons, radiologists, psychotherapists, pain physicians) working in centers specialized in endometriosis, general practitioners, researchers specialized in endometriosis and patient experts.

2 | MATERIAL AND METHODS

The modified Delphi process is a common methodology which has previously been used to develop a standard set of indicators.¹² This methodology is used to reach agreement among experts on a given topic through several rounds of surveys that aim to collect the point of view of these experts. However, in the modified Delphi method, rather than continue with many rounds until agreement was reached, two survey rounds and a final open discussion are performed to reach consensus.¹² An overview of the whole process is described in [Figure 1](#).

2.1 | Review of the literature and identification of the list of metrics to be evaluated

A systematic review of the literature was conducted to identify the PROMs and CROMs used in observational studies and clinical trials on endometriosis. The MEDLINE/PubMed database was screened for publications in English from 1984 to January 2021 including




FIGURE 1 A two-round modified Delphi consensus study to determine a set of patient-centered outcome measurements for routine use in endometriosis care.

the following MeSH (Medical Subject Headings) terms: “quality outcomes”, “quality indicators”, “quality of life”, “patient reported outcome”, “clinician reported outcomes”, “endometriosis”. Only validated (ie having undergone a validation study) PROMs and CROMs were retained. A thorough review of the identified PROMs and their potential to be used in routine endometriosis care has already been described elsewhere.¹³ The PROMs and CROMs were grouped according to the type of indicator measured: four subgroups for the CROMs (clinical indicators, imaging indicators, biological indicators and surgical indicators) and 11 for the PROMs (symptomatic impact, pain, fatigue, sexual activity, gastrointestinal symptoms, urinary symptoms, psychological impact, work productivity, endometriosis

quality of life, general quality of life and miscellaneous). A complete description of the PROMs and CROMs used in the survey was made available to all participants (Table S1).

2.2 | Composition of the expert panel

The steering committee (AF, JB, PS, AT, ANB) selected an international and diverse panel of healthcare professionals (gynecologists, surgeons, radiologists, psychotherapists, pain physicians) working in centers specialized in endometriosis, non-specialized gynecologists, general practitioners, researchers specialized in

endometriosis and patient representatives to ensure a multidisciplinary and comprehensive view, including the patient viewpoint. The selection of participants contacted to be part in the expert panel was based on three complementary approaches: (i) some experts were selected based on the level of expertise in PROMs and CROMs in endometriosis according to the literature using MEDLINE (“quality outcomes”, “quality indicators”, “quality of life”, “patient reported outcome”, “clinician reported outcomes”, “endometriosis”) and communications on this topic in the different international congresses on endometriosis (WCE and SEUD); (ii) additional experts were added from suggestions made by the steering committee of non-specialized gynecologists and general practitioners interested in endometriosis care; (iii) the panel was completed with experts referenced by the World Endometriosis Society. The panel experts were recruited from different geographic regions – mainly developed countries in Europe, America and Australia/Oceania – to ensure the representation of a wide range of clinical practices. Patient representatives were recruited from patient associations across the geographic regions. All associations listed in the World Endometriosis Organizations (<https://endometriosis.org/support/world-endometriosis-organisations-weo/>) were contacted by email twice. Only three national patient organizations agreed to participate: ENDOFRANCE (<https://www.endofrance.org/>) from France, *Endometriose Stichting* (<https://www.endometriose.nl/>) from the Netherlands, and *Asociacion de Afectadas de Endometriosis* (<https://adaec.es/>) from Spain. The expert panel did not receive remuneration for their participation.

2.3 | Delphi Round 1

The Qualtrics platform (<https://www.qualtrics.com/>) was used to invite the participants to rate the PROMs and CROMs. Non-responders were recontacted by email twice.

Each participant evaluated the 47 pre-selected PROMs and the 30 pre-selected CROMs using a single Likert scale of 1–9 for their relevance and feasibility in assessment of women with endometriosis, where 1 meant completely disagree (not relevant or feasible for routine practice) and 9 completely agree (relevant and feasible for routine practice). By relevance we meant that the CROM/PROM indicators were pertinent for endometriosis care, that they measure outcomes that really matter to patients with endometriosis and that their measurement could be used to improve the care pathway at an individual level. By feasibility, we meant that the indicators could be easily measured in routine clinical practice with minimal additional time or cost.

All participants were provided with a short description and literature references of each of the PROM/CROM indicators. The whole study was conducted in English. Participants were also invited to suggest additional outcomes that had not been included in the initial list.

At the end of Round 1, all the indicators with a median score ≥ 7 and where at least 50% of the panel ratings were ≥ 7 , were retained

for Round 2. Indicators not meeting the threshold were discarded by the steering committee.¹²

2.4 | Delphi Round 2

Round 2 was another self-administered online survey sent to those who participated in the first round. Each participant received the results of the first round including the median rating, frequency distributions and a reminder of their personal ratings in Round 1. For Round 2 the participants were asked to consider each indicator after reviewing their prior rating as well as the panel ratings for Round 1. An indicator was retained in the final set if the median score was ≥ 7 and at least 65% of the panel ratings were ≥ 7 .¹²

2.4.1 | Virtual meetings to discuss and finalize the selected outcome set

Due to the geographic diversity and the COVID-19 pandemic, a series of videoconference meetings scheduled on three different days – October 25, 26 and 27, 2021 – at three different times of the day enabled engagement of the international experts. The meeting dates were decided using a Doodle with different times that were created to suit to the different time zones. The chosen dates were those in which more participants declared themselves to be available. Anyone who participated in Round 2 was invited to participate in these meetings. During each meeting, the results from Round 2 were presented and indicators that were not selected but which were close to the agreement threshold (65%) were discussed, as well as any categories or indicators that participants raised for clarification or inclusion. Each meeting was chaired by two of the authors (ANB and AF). Experts attended only one of the three meetings.

2.5 | Statistical analyses

A descriptive analysis of the characteristics of the participants and the results of each Delphi round was conducted. Results are represented as medians (Q1, Q3, interquartile range) for continuous variables, and percentages (%) for categorical variables. The medians and the interquartile ranges of the rating were measured in each of the Delphi rounds and the percentages described the level of agreement among panelists. The analyses were performed using Microsoft EXCEL Software.

2.6 | Ethics statement

The study was registered on clinicaltrials.gov (Identifier: NCT04820582). All procedures performed in studies involving human participants were in accordance with the ethical standards

of the institutional and/or national research committee. Our study did not involve any intervention and was therefore exempt from the French regulations on biomedical research (modified version of the Law 2004–806, dated August 9, 2004). This study received ethics approval from the Comité d’Ethique de la Recherche en Obstétrique et Gynécologie (CEROG) on May 21, 2021 (number 2021-GYN-0409).

3 | RESULTS

3.1 | Preselection of indicators

The preselected 47 PROMs and 30 CROMs constituted the starting set for Round 1 (Table 1). The distribution of the PROMs in the 11 subgroups was as follows: (i) Symptomatic Impact ($n=4$); (ii) Pain ($n=7$); (iii) Fatigue ($n=2$); (iv) Sexual Activity ($n=5$); (v) Gastrointestinal Symptoms ($n=4$); (vi) Urinary Symptoms ($n=2$); (vii) Psychological Impact ($n=6$); (viii) Work Productivity ($n=2$); (ix) Endometriosis Quality of Life ($n=2$); (x) General Quality of Life ($n=6$); (xi) Miscellaneous ($n=7$). The distribution of the CROMs in the four subgroups is as follows groups: (i) Clinical Indicators ($n=15$); (ii) Imaging Indicators ($n=6$); (iii) Biological Indicators ($n=4$); (iv) Surgical Indicators ($n=5$).

3.2 | Participants

Overall, 166 experts and patient representatives were contacted to participate in the study and 67 agreed to participate. Table 2 summarizes the characteristics of those who agreed to participate.

3.3 | Delphi Round 1

Fifty-one (76%) of the 67 experts who agreed to participate, participated in Round 1 (Figure 1). Forty-six outcome measures were discarded after this round: 14 CROMs and 32 PROMs (Table 1). Open text boxes supplemented the Likert scale, providing some examples of the rationale for those CROMs that were discarded. The Biberoglu & Behrman scale was discarded because “some elements of the clinical examinations are only possible by highly trained professionals and specialists; it cannot be offered in a situation of first level screening”. The revised American Society of Reproductive Medicine (rASRM) surgical classification which is widely used to stage endometriosis was also discarded. The reasons given included “this surgical classification is not relevant for patients who are not undergoing surgery, and not all endometriosis patients undergo surgery” as well as the fact that “the classification is poor and does not allow the evaluation of deeply infiltrative endometriosis (DIE)”. Some of the PROMs that were discarded included a series of tools measuring pain (Pain Catastrophizing Scale, Pain Vigilance and Awareness Questionnaire, Pain Anxiety Symptom Scale, PAINDETECT) as they were viewed as “not fully validated and accepted” and that “they are more suited

for research than routine clinical practice settings”. Furthermore, most PROMs measuring the psychological impact of endometriosis were also discarded (Beck Depression Inventory, Patient Health Questionnaire, Spielberg State Trait Anxiety Inventory, General Anxiety Disorder, Beck Anxiety Inventory). In addition, all suggested PROMs measuring fatigue were discarded because they were considered to be “more for research than clinical practice” and because “they were not specific to endometriosis”. The same occurred with the indicators measuring the impact of urinary symptoms: both indicators (the Urinary Symptom Profile and International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules) were considered to be used “mainly for research” and “only important for those patients who undergo bladder surgery”. Finally, most of the PROMs measuring quality of life (SF-12, EQ-5D, PROMIS Global Health, WHOQoL BREF, Nottingham Health Profile) were discarded because they were “mainly suitable for research purposes”.

Two indicators that had not been included in the initial list were added by the participants: the Antral Follicle Count measured by transvaginal ultrasound was added since it was considered “a better indicator for the evaluation of ovarian failure”; and the Raising Awareness Tool of Endometriosis (RATE) questionnaire (developed by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG)) was also added, since “it is a more practical alternative tool to measure sexual activity”.

3.4 | Delphi Round 2

Forty-four (86%) of the 51 experts who participated in Round 1 provided responses in Round 2 (Figure 1). In this round, 14 outcome measures were discarded (Table 1) – seven CROMs (the Andersch and Milsom scale, magnetic resonance imaging (MRI)-based Enzian score, Ultrasound-based endometriosis staging system, anti-Müllerian hormone serum level, antral follicle count measured by transvaginal ultrasound, Enzian classification, and the Endometriosis Fertility Index); and seven PROMs (the Female Sexual Function Index, Sexual Activity Questionnaire, Gastrointestinal Quality of Life Index, Hospital Anxiety and Depression Scale, SF-36, FertiQoL and the RATE questionnaire). Nineteen indicators constituting the final list were discussed in the expert meetings. The CROM (antral follicle count measured by transvaginal ultrasound) and PROM (RATE questionnaire) that were proposed for inclusion during Round 1 were both discarded in Round 2. Some of the CROMs that were discarded are used in many studies and the rationale for discarding them is worth highlighting. For example, the clinical indicator Andersch and Milsom was discarded because it is “an indicator based on unconfirmed assumptions” and “not the most useful scale”. The imaging indicator Ultrasound-based Endometriosis Staging System (UBESS) was discarded because “being very operator dependent and highly trained sonographers are needed, a resource that is not always available”. Two surgical indicators were discarded: the Endometriosis Fertility Index (EFI) and the Enzian classification. The EFI was discarded because

TABLE 1 Summary of all the items analyzed, including those for which no consensus was reached.

| Number # | Items | Round 1 | | | Round 2 | | |
|---|---|----------------|-------------------|----------|----------------|-------------------|----------|
| | | Median (Q1–Q3) | % agreement (7–9) | Status | Median (Q1–Q3) | % agreement (7–9) | Status |
| Clinician Reported Outcome Measures (CROM) | | | | | | | |
| CROM – Clinical indicators | | | | | | | |
| 1 | NSAID consumption | 7 (5.7–8) | 67 | Included | 7 (6–8) | 72 | Included |
| 2 | Biberoglu & Behrman score | 6 (5–8) | 40 | Excluded | | | |
| 3 | Oxycodone/opioids consumption | 7 (5–8) | 59 | Included | 7 (6–8) | 67 | Included |
| 4 | Bristol stool scale | 5 (4–6.5) | 25 | Excluded | | | |
| 5 | Frequency of daily bowel movements (≥ 3 stools/D) | 6 (4–7) | 37 | Excluded | | | |
| 6 | Andersch and Milsom scale | 7 (4–8) | 50 | Included | 7 (5–7.5) | 53 | Excluded |
| 7 | Clinical Global Impressions (CGI) Scale | 6 (5, 7.5) | 38 | Excluded | | | |
| 8 | Uroflowmetry and Post-void residual | 4 (3–7) | 27 | Excluded | | | |
| 9 | Identification of black-bluish nodule at vaginal fornix examination | 7 (5.7–8.2) | 65 | Included | 7 (6–8) | 67 | Included |
| 10 | Assessment of cul-de-sac nodularity by bimanual pelvic examination | 8 (5.5–8.5) | 61 | Included | 7 (6–8) | 68 | Included |
| 11 | Evoked pain assessment during digital vaginal examination | 7 (5–8.3) | 63 | Included | 7 (6.5–8) | 74 | Included |
| 12 | Quantitative sensory testing | 6 (4–7) | 32 | Excluded | | | |
| 13 | Allodynia and hyperalgesia assessed by examination of dermatomes | 6 (4–7) | 29 | Excluded | | | |
| 14 | Neuropathic pain diagnostic questionnaire (DN4) | 6 (4–8) | 44 | Excluded | | | |
| 15 | Duration of infertility | 7 (6–8) | 69 | Included | 7 (6–8) | 70 | Included |
| CROM – Imaging indicators | | | | | | | |
| 16 | Deep pelvic endometriosis index (dPEI) classification | 7 (5.7–8) | 57 | Included | 7 (6–8) | 69 | Included |
| 17 | MRI-based Enzian score | 7 (5–8) | 52 | Included | 7 (5.5–8) | 60 | Excluded |
| 18 | IDEA consensus for MRI | 7 (5.7–8) | 57 | Included | 7 (6–8) | 71 | Included |
| 19 | IDEA consensus for ultrasound | 7 (5–8) | 57 | Included | 7 (6.2–8) | 74 | Included |
| 20 | Bone mineral density (BMD) evaluation – X-ray densitometry | 5 (3–6) | 22 | Excluded | | | |
| 21 | Ultrasound-based endometriosis staging system (UBESS) | 7 (6–8) | 57 | Included | 7 (6–8) | 56 | Excluded |

TABLE 1 (Continued)

| Number # | Items | Round 1 | | | Round 2 | | |
|---|--|----------------|-------------------|----------|----------------|-------------------|----------|
| | | Median (Q1–Q3) | % agreement (7–9) | Status | Median (Q1–Q3) | % agreement (7–9) | Status |
| CROM – Biological indicators | | | | | | | |
| 22 | Anti-Müllerian hormone (AMH) serum level | 7 (5–8) | 50 | Included | 7 (6–7.5) | 59 | Excluded |
| 23 | Follicle stimulating hormone (FSH) level | 6 (3.5–7) | 38 | Excluded | | | |
| 24 | Serum carcinoembryonic antigen levels CA125 | 5 (3–6) | 18 | Excluded | | | |
| 25 | Estradiol levels | 4 (2–6) | 20 | Excluded | | | |
| 78 | Antral follicle count measured by transvaginal ultrasound | | | Added | 7 (5–7) | 53 | Excluded |
| CROM – Surgical indicators | | | | | | | |
| 26 | Revised American Society for Reproductive Medicine (rASRM) classification | 6 (5–8) | 45 | Excluded | | | |
| 27 | Enzian classification | 7 (5–8) | 56 | Included | 7 (6–8) | 63 | Excluded |
| 28 | Endometriosis Fertility Index (EFI) | 7 (5–8) | 52 | Included | 7 (6–8) | 56 | Excluded |
| 29 | Assessment of cul-de-sac nodularity and assessment of rectal involvement by rectovaginal examination under general anesthesia | 6 (4–7) | 35 | Excluded | | | |
| 30 | Surgical classification of deep endometriosis | 7 (6–8.7) | 69 | Included | 7 (7–8) | 81 | Included |
| Patient Reported Outcome Measures (PROM) | | | | | | | |
| PROM – Symptomatic impact | | | | | | | |
| 31 | Endometriosis Symptom Diary (ESD) | 7 (6–8) | 73 | Included | 8 (7–8) | 80 | Included |
| 32 | Endometriosis Impact Scale (EIS) | 7 (6–8) | 65 | Included | 7 (7–8) | 77 | Included |
| 33 | Endometriosis Impact Questionnaire (EIQ) | 7 (6–8) | 69 | Included | 8 (7–8) | 79 | Included |
| 34 | Menstrual Distress Questionnaire (MDQ) | 7 (5.5–8) | 61 | Included | 7 (6–8) | 69 | Included |
| PROM – Pain | | | | | | | |
| 35 | Endometriosis Associated Pelvic Pain (EAPP) | 7 (6–8) | 73 | Included | 7.5 (7–8) | 84 | Included |
| 36 | Pain Catastrophizing Scale (PCS) | 6 (6–7) | 39 | Excluded | | | |
| 37 | Pain Vigilance + Awareness Questionnaire (PVAQ) | 6 (4.7–7) | 34 | Excluded | | | |

TABLE 1 (Continued)

| Number # | Items | Round 1 | | | Round 2 | | |
|----------------------------------|--|----------------|-------------------|----------|----------------|-------------------|--|
| | | Median (Q1–Q3) | % agreement (7–9) | Status | Median (Q1–Q3) | % agreement (7–9) | Status |
| 38 | Pain Anxiety Symptom Scale (PASS) | 6 (4–7) | 37 | Excluded | | | |
| 39 | PAINDETECT questionnaire (PDQ) | 6 (5–7) | 36 | Excluded | | | |
| 40 | German Endometriosis-Questionnaire | 6 (4–7) | 34 | Excluded | | | |
| 41 | ENDOL-4D/ENDOPAIN-4D | 7 (5.5–8) | 56 | Included | 7 (7–8) | 77 | Included |
| PROM – Fatigue | | | | | | | |
| 42 | PROMIS Fatigue Short form | 6 (4.5–7) | 38 | Excluded | | | |
| 43 | Piper Fatigue Scale (PFS) | 6 (4–7) | 32 | Excluded | | | |
| PROM – Sexual activity | | | | | | | |
| 44 | Female sexual function index (FSFI) | 7 (6–7) | 60 | Included | 7 (6–7) | 64 | Excluded Included in the list of complementary outcomes |
| 45 | Sexual Activity Questionnaire (SAQ) | 7 (5–7) | 51 | Included | 7 (6–7) | 64 | Excluded Included in the list of complementary outcomes |
| PROM – Gastrointestinal symptoms | | | | | | | |
| 46 | Sexual Health Outcomes in Women Questionnaire (SHOW-Q) | 6 (5–7) | 46 | Excluded | | | |
| 47 | Golombok Rust Inventory Sexual Satisfaction (GRISS) | 5 (4–6) | 20 | Excluded | | | |
| 48 | Female Sexual Distress Scale (FSDS) | 6 (5–7) | 40 | Excluded | | | |
| PROM – Gastrointestinal symptoms | | | | | | | |
| 49 | Gastrointestinal Quality Life Index (GIQLI) | 7 (5–7) | 53 | Included | 7 (6–7) | 64 | Excluded Included in the list of complementary outcomes |
| PROM – Urinary symptoms | | | | | | | |
| 50 | Knowles-Eccersley-Scott-Symptom (KESS) | 6 (5–7) | 29 | Excluded | | | |
| 51 | Fecal Incontinence Quality of Life (FIQL) | 5 (4–7) | 27 | Excluded | | | |
| 52 | Wexner | 5 (3–6) | 14 | Excluded | | | |
| PROM – Psychological impact | | | | | | | |
| 53 | Urinary Symptom Profile (USP) | 6 (5–7) | 47 | Excluded | | | |
| 54 | ICIQ-FLUTS | 6 (4–7) | 38 | Excluded | | | |
| PROM – Psychological impact | | | | | | | |
| 55 | Hospital Anxiety and Depression Scale (HADS) | 7 (5–7) | 50 | Included | 7 (5–7) | 57 | Excluded Included in the list of complementary outcomes |
| 56 | Beck Depression Inventory (BDI) | 6 (5–7) | 44 | Excluded | | | |

TABLE 1 (Continued)

| Number # | Items | Round 1 | | | Round 2 | | | Discussion |
|--------------------------------|--|----------------|-------------------|----------|----------------|-------------------|----------|--|
| | | Median (Q1–Q3) | % agreement (7–9) | Status | Median (Q1–Q3) | % agreement (7–9) | Status | |
| 57 | Patient Health Questionnaire (PHQ-9) | 7 (5–7) | 49 | Excluded | | | | |
| 58 | Spielberg State Trait Anxiety Inventory (STAI) | 5 (4–7) | 26 | Excluded | | | | |
| 59 | General Anxiety Disorder (GAD-7) | 6 (4–7) | 36 | Excluded | | | | |
| 60 | Beck Anxiety Inventory (BAI) | 6 (5–7) | 39 | Excluded | | | | |
| 61 | PROM work productivity Health Related Productivity Questionnaire (HRPQ) | 6 (4.7–7) | 47 | Excluded | | | | |
| 62 | Work Productivity and Activity Impairment Questionnaire (WPAI-SHP) | 7 (5–8) | 51 | Included | 7 (6–8) | 66 | Included | Included |
| 63 | PROM – Endometriosis quality of life Endometriosis Health Profile – 5 (EHP-5) | 8 (7–8.5) | 78 | Included | 8 (7–8.2) | 86 | Included | Included |
| 64 | Endometriosis Health Profile – 30 (EHP-30) | 8 (7–8) | 78 | Included | 7.5 (7–8) | 86 | Included | Included in the list of complementary outcomes |
| PROM – General quality of life | | | | | | | | |
| 65 | SF-12 | 6 (5–7) | 41 | Excluded | | | | |
| 66 | SF-36 | 7 (5.2–8) | 57 | Included | 7 (6–8) | 61 | Excluded | |
| 67 | EQ-5D | 6 (5–7) | 39 | Excluded | | | | |
| 68 | PROMIS Global Health | 6 (4–7) | 32 | Excluded | | | | |
| 69 | WHOQoL BREF | 6 (4–7) | 31 | Excluded | | | | |
| 70 | Nottingham Health Profile (NHP) | 6 (4–7) | 32 | Excluded | | | | |
| PROM – Miscellaneous | | | | | | | | |
| 71 | International Fitness Scale | 4 (3–6) | 18 | Excluded | | | | |
| 72 | Acceptance of Illness Scale (AIS) | 5 (3–6) | 20 | Excluded | | | | |
| 73 | Coping Strategies Inventory (CSI) | 5 (3–6) | 22 | Excluded | | | | |
| 74 | FertiQoL | 7 (5–7.7) | 52 | Included | 7 (5–7) | 60 | Excluded | |
| 75 | Pittsburg Sleep Quality Index (PSQI) | 5 (3.7–6) | 18 | Excluded | | | | |
| 76 | Insomnia Severity Index (ISI) | 4,5 (3–6) | 16 | Excluded | | | | |
| 77 | Epworth Sleepiness Scale (ESS) | 4 (3–6) | 12 | Excluded | | | | |
| 79 | Raising Awareness Tool for Endometriosis (RATE) questionnaire | | | Added | 7 (6–8) | 63 | Excluded | |

TABLE 2 Characteristics of participants in the different rounds of the Delphi study.

| Characteristic | Round 1 | | Round 2 | | Final discussion | |
|---------------------------|-----------|------------|-----------|------------|------------------|------------|
| | n | % | n | % | n | % |
| Characteristic | | | | | | |
| Total participants | 51 | | 44 | | 20 | |
| Female | 28 | 55% | 27 | 61% | 11 | 55% |
| Male | 23 | 45% | 18 | 41% | 9 | 45% |
| Location | | | | | | |
| Asia | 2 | 4% | 2 | 5% | 2 | 10% |
| Israel | 2 | 4% | 2 | 5% | 2 | 10% |
| Europe | 36 | 71% | 31 | 70% | 14 | 70% |
| Italy | 4 | 8% | 3 | 7% | 3 | 15% |
| France | 17 | 33% | 16 | 36% | 7 | 35% |
| Denmark | 1 | 2% | 0 | 0% | 0 | 0% |
| Belgium | 1 | 2% | 1 | 2% | 1 | 5% |
| UK | 3 | 6% | 2 | 5% | 1 | 5% |
| Spain | 2 | 4% | 2 | 5% | 0 | 0% |
| Portugal | 1 | 2% | 0 | 0% | 0 | 0% |
| Germany | 2 | 4% | 2 | 5% | 1 | 5% |
| Netherlands | 5 | 10% | 5 | 11% | 1 | 5% |
| America | 10 | 20% | 9 | 20% | 3 | 15% |
| Argentina | 1 | 2% | 1 | 2% | 1 | 5% |
| Brazil | 1 | 2% | 1 | 2% | 0 | 0% |
| US | 6 | 12% | 5 | 11% | 2 | 10% |
| Canada | 2 | 4% | 2 | 5% | 0 | 0% |
| Australia | 3 | 6% | 3 | 7% | 1 | 5% |
| Australia | 2 | 4% | 2 | 5% | 1 | 5% |
| New Zealand | 1 | 2% | 1 | 2% | 0 | 0% |
| Status | | | | | | |
| Total participants | 51 | | 44 | | 20 | |
| Obstetrician/gynecologist | 29 | 57% | 25 | 57% | 12 | 60% |
| Radiologist | 2 | 4% | 1 | 2% | 0 | 0% |
| Psychotherapist | 1 | 2% | 1 | 2% | 1 | 5% |
| Pain Physician | 1 | 2% | 1 | 2% | 1 | 5% |
| General Practitioner | 1 | 2% | 1 | 2% | 1 | 5% |
| Researcher | 6 | 12% | 5 | 11% | 1 | 5% |
| Patient | 11 | 22% | 11 | 25% | 4 | 20% |

Note: Bold values show the total of each section. For example, total number of participants is the addition of female and male participant. The total number of participants in Europe is the addition of all participants of each of the European countries.

“it includes measurements that are not related to endometriosis” and “mainly measures infertility that only affects a certain percentage of patients with endometriosis”. The Enzian classification was discarded because “it is mainly used in German speaking countries and has poor external validation”. All PROMs measuring the impact of endometriosis in sexual activity, gastrointestinal symptoms and psychological impact were discarded because the proposed PROMs were not specific to endometriosis. Finally, the SF-36, despite its use in clinical research studies in endometriosis,

was discarded due to “its length, complexity and lack of specificity in endometriosis”. Such an instrument was deemed “suitable for research studies but not for routine care”.

3.5 | Final discussion

Of the 44 experts who participated in Round 2, 21 (47%) participated in one of the expert discussion sessions. During these

discussions, an overview of the Round 2 results was presented and indicators that had not been selected but which had a percentage of agreement close to the threshold were discussed, as well as other indicators that participants raised for clarification or inclusion. For example, Enzian had a median score of 7 in Round 2 but the percentage of agreement of 63% was lower than the required threshold of 65%. The Enzian classification included in the Delphi phase of this study was the original version from 2003.¹⁴ However, during the final discussion the experts suggested the recently updated version, the #Enzian classification, which can be adopted by gynecologists, surgeons, sonographers and radiologists using the same principles, independently of whether the evaluation is surgical, uses ultrasounds or MRI.¹⁵ During the robust discussion comparing the #Enzian classification with the surgical classification of DIE,¹⁶ the latter was discarded despite reaching a median score of 7 and a percentage agreement of 69%, due to its close resemblance to #Enzian, and the fact that the expert group considered #Enzian to be more versatile.

A decision was made to create a list of complementary outcomes which were considered unsuitable for routine care in endometriosis, yet covered important dimensions. For example, all the PROMs measuring sexual activity and psychological impact were discarded after the two Delphi rounds. However, all the participants in the expert meetings agreed that these two dimensions deserved measurement in routine endometriosis care. Regarding sexual activity, both the Female Sexual Function Index (FSFI)^{17,18} and Sexual Activity Questionnaires (SAQ)^{19,20} are of proven validity and reliability in the field of endometriosis and are included among the complementary outcomes. Both have their drawbacks: the FSFI has a low sensitivity for endometriosis¹⁸ and is not suitable for patients who are not sexually active; and while the SAQ take into consideration that patients may not be sexually active, they are not specific to endometriosis, and particularly for dyspareunia.²¹ The panel's conclusion was that, although to date there is no suitable tool to measure the impact of endometriosis on sexual activity, the FSFI and SAQ should be included in the complementary outcomes due to the importance of measuring this commonly neglected dimension. Nevertheless, there was agreement of an urgent need to create an adapted tool to measure sexual activity.

The evaluation of the psychological impact was also deemed important during discussion. Although all the proposed PROMs were considered were not validated to measure the psychological impact in endometriosis patients, until a suitable PROM is created and validated, the panel recommended adding the Hospital Anxiety and Depression Scale (HADS) to the complementary outcomes.²² Finally, the Gastrointestinal Quality Life Index (GIQLI) was added in the list of complementary outcomes for use only with those patients for whom it is relevant, despite having been discarded in Round 2.

In addition, two diaries were selected after the two Delphi rounds: the Endometriosis Symptom Diary (ESD), and Endometriosis Impact Scale (EIS). During the expert discussion, participants agreed that not only is recording symptoms daily, cumbersome for patients

and may compel them to focus on their disease, but the results are challenging for clinicians to interpret. However, some considered that these kinds of PROMs could be useful within a limited time-frame for certain patients, particularly in the primary care setting. For this reason, they were included in the list of complementary outcomes.

3.6 | Selected outcomes set

Of the 19 outcome measures selected in Round 2, 16 outcome measures (10 CROMs and six PROMs) that were judged relevant and feasible to use in routine endometriosis care were selected as the minimal set of patient-centered outcomes (Table 2). Seven additional PROMs, considered to be relevant in specific clinical conditions only, were included in a complementary outcomes list, tailored to individual patients' needs (Table 3).

4 | DISCUSSION

We developed a set of patient-centered measures including PROMs and CROMs specifically designed for routine use in endometriosis care through a modified Delphi study with an international group of known experts and patient representatives. The final set includes: PROMs covering domains of pain-related symptoms, symptomatic impact, work productivity, disease-related quality of life, sexual activity, gastrointestinal symptoms and psychological impact; and CROMs covering clinical, imaging and surgical indicators. Despite patient-to-patient variability in symptomatology, these domains comprise the common features requested for all patients suffering from endometriosis. Collecting these outcome measures in routine practice is therefore a critical first step toward patient-centered care.³ Certain issues are not easily brought up during a consultation and may be consequently unaddressed by the clinician when deciding the therapeutic approach. It has been demonstrated that including patient-centered outcome metrics in routine care and monitoring changes throughout the patient journey would provide clinicians with an opportunity to discuss their patients' expectations of a given treatment and potentially identify incompatibilities or unrealistic expectations.^{3,11} Its implementation in routine clinical practice can complete the clinician's medical consultation and facilitate patient-centered care by encompassing the patient's view of their disease. This is particularly relevant in endometriosis, since the patient's and physician's perception of the disease can differ significantly.²³ Overall, they can be used as shared decision-making tools.¹¹

The set of patient-centered outcomes measures presented in our study has been primarily chosen for its use in routine care. As clinical practice and research are two sides of the main coin, one may question whether the measurement set we propose can also be used in research and, in turn, those already developed for research purpose can overlap our results. Indeed, following the same method as ours, other research groups have recently published a core outcome set

TABLE 3 Final and complementary set of patient-centered outcomes for endometriosis care.

| Main set of patient-centered outcomes | Complementary patient-centered outcomes |
|---|--|
| Patient Reported Outcome Measures (PROM) | Patient Reported Outcome Measures (PROM) |
| PROM – Symptomatic impact | PROM – Symptomatic impact |
| Endometriosis Impact Questionnaire (EIQ) ²⁹ | Endometriosis Symptom Diary (ESD) ³⁰ |
| Menstrual Distress Questionnaire (MDQ) ³¹ | Endometriosis Impact Scale (EIS) ³⁰ |
| PROM – Pain | PROM – Sexual activity |
| Endometriosis Associated Pelvic Pain (EAPP) ³² | Female sexual function index (FSFI) ¹⁷ |
| ENDOL-4D/ENDOPAIN-4D ³³ | Sexual Activity Questionnaire (SAQ) ¹⁹ |
| PROM – Work productivity | PROM – Gastrointestinal symptoms |
| Work Productivity and Activity Impairment Questionnaire (WPAI-SHP) ³⁴ | Gastrointestinal Quality Life Index (GIQLI) ³⁵ |
| PROM – Endometriosis quality of life | PROM – Endometriosis quality of life |
| Endometriosis Health Profile-5 (EHP – 5) ³⁶ | Endometriosis Health Profile-30 (EHP – 30) ³⁷ |
| Clinician Reported Outcome Measures (CROM) | PROM – Psychological impact |
| CROM – Clinical Indicators | Hospital Anxiety and Depression Scale (HADS) ²² |
| NSAID consumption | |
| Oxycodone/opioids consumption | |
| Identification of black-bluish nodule at vaginal fornix examination ³⁸ | |
| Assessment of cul-de-sac nodularity by bimanual pelvic examination ³⁹ | |
| Evoked pain assessment during digital vaginal examination ⁴⁰ | |
| Duration of infertility | |
| CROM – Imaging indicators | |
| Deep pelvic endometriosis index (dPEI) classification ⁴¹ | |
| IDEA consensus for MRI ⁴² | |
| IDEA consensus for ultrasound ⁴³ | |
| CROM – Surgical indicators | |
| #Enzian classification ¹⁵ | |

to standardize outcome selection, collection and reporting across future randomized controlled trials and systematic reviews evaluating potential treatments for endometriosis.⁶ Our proposal differs mainly in the fact that we not only define the core dimensions that should be measured (pain, quality of life, psychologic impact) but additionally propose the use of currently validated measures for how they must be measured, ie what are the specific metrics to measure each dimension. In the Delphi process we used specific PROMs and CROMs already validated in endometriosis population, therefore guaranteeing the reliability of the measurement set we propose. Our approach toward measurement is closer to the one led by the World Endometriosis Research Foundation – the Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHeCt), which aims to standardize the collection of a minimum of clinical information in endometriosis clinical trials using dedicated self-assessed questionnaire.^{7–10} Nonetheless, the principal aim of this initiative was to harmonize the various questionnaires used in distinct epidemiological or biological research projects on endometriosis and to facilitate international collaborative research. However, the questionnaires used in this approach have not been developed according to the Health-Related patient measurement methodology (Cosmin) and therefore cannot be reliably used in the context of standard care.

One of the strengths of the present study is the mix of both patient representatives and healthcare practitioners involved in the field of endometriosis. The DELPHI method has the advantage over other consensus methods that individuals can be included anonymously and without interacting directly with each other, which prevents the views of a minority from dominating the group.²⁴ This made it possible to select outcomes that are easy to understand and represent the patient's perspective but are also useful from a medical point of view.³

As there is no recommended threshold for consensus studies, we chose a level of agreement based on a two-thirds majority, which represents a commonly used level.²⁵ A stronger level was not chosen (eg three-quarters, or absolute majority) as our survey did not aim to present compulsory recommendations for use (for example modifications of recommendations for good clinical practice that could require stronger agreement to be accepted), but instead to offer an approach that gave clinicians the choice of measures to use.

One of the main limitations of this study is that the number and geographic diversity of patient representatives in the expert group were low. Patient associations from all over the world were contacted but few replied. This lack of response is a major challenge of efforts aimed to develop a more patient-centered approach: patient

community involvement is of utmost importance but their participation remains low.²⁶ Nevertheless, the ratio physician:patient representative remained stable through the different rounds, meaning that patient participation was equivalent in each round and in the final discussion meetings. Additionally, it is important to keep in mind that within the group of clinicians, the expert panel was made up of a large percentage of specialists in endometriosis. However, our work was designed to include the perspective of the standard gynecologists and general physicians. As a result, the selected set of patient-centered measures is relevant to the common features of patients for implementation in routine care. From this list, clinicians can select according to their needs and their day-to-day reality.

Another limitation of the study is the over-representation of experts from European, high-income countries because of difficulties encountered in identifying and engaging expert healthcare professionals or patient representatives from elsewhere. Thus, the outcome set may not be generalizable to or acceptable to experts and patients from low- and middle-income countries where there is a large gap in both diagnosis and treatment as well as research in endometriosis between high-income countries and low/middle-income countries.^{27,28} Adaptions to the outcome set may be needed for low- and middle-income countries.

Clinicians currently use CROMs but may be reluctant to use PROMs in routine care due to the fear of additional burden or extra workload.³ The recent development of digital tools for PROM collection as well as advances in the development of standards for interoperability, make the idea of merging both CROMs and PROMs in a same visual interface a feasible reality. One possibility may be that these outcomes measures are displayed on the clinician dashboard during consultation. The next step of this project will be to test the implementation and evaluate the feasibility of data collection using digital tools.

5 | CONCLUSION

We have developed a set of patient-centered measures including PROMs and CROMs in endometriosis care through an international consensus. Considering the large variability in terms clinical setting, context and patient symptomatology in endometriosis, the selected outcomes comprise the common features for all patients suffering from endometriosis and may be implemented in routine care.

AUTHOR CONTRIBUTIONS

A.N.-B., A.T., P.S., J.B., A.F.: Steering committee. A.N.-B., A.F.: Selection of expert panel and preparation of Delphi questionnaire. A.N.-B.: Data acquisition. A.N.-B., E.L.R.: Statistical analysis. A.N.-B., E.L.R., A.F.: Interpretation of the data. A.N.-B., E.L.R., P.S., P.V., A.F.: Drafting the article. A.F.: Study supervision.

ACKNOWLEDGMENTS

We would like to acknowledge all the participants of The VALue Based HEalth CaRe In Endometriosis (VALHERIE) Study Group

expert panel for their participation in this study: Lars Arendt-Nielsen (Denmark), Françoise Assamoi (France), Irene Atienza (Spain), Christian Becker (UK), Giuseppe Benagiano (Italy), Blanca de Bie (Netherlands), Nicole Bornsstein (France), Nicolas Bourdel (France), Shlomo Cohen (Israel), Josepha Collignet (France), Emile Darai (France), Margaux Darcel (France), Linda Deal (USA), Bruno Dedet (France), Elaine Denny (UK), Thomas D'Hooghe (Belgium), Nicole M. Donnellan (USA), Mariska van Drogenbroek (Netherlands), Vered Eisenbger (Israel), Federica Facchin (Italy), Emilie Faller (France), Cindy Farquhar (New Zealand), Simone Ferrero (Italy), Violette Frentrop (Netherlands), Xavier Fritel (France), Marie-Rose Gales (France), Juan Garcia Velasco (Spain), Adalguisa Guerra (Portugal), Harald Krentel (Germany), Marina Kvasokoff (France), Alain Lam (Australia), Nicholas A. Leyland (Canada), Justine Lucotte (France), Germaine Louis (USA), Stephanie Mathieson (Australia), Charles Miller (USA), Annamiek Nap (Netherlands), Camran Newhat (USA), Anne Oppenheimer (France), Erick Petit (France), Edgardo Rolla (Argentina), Horace Roman (France), Catherine Rongieres (France), Carlos A. Souza (Brazil), Mickael Stark (Germany), Jane Wijbers (Netherlands), Paul J. Yong (Canada), Krina Zondervan (UK). We also acknowledge the patient associations EndoFrance, Endometriose Stichting and Asociacion de Afectadas de Endometriosis.

FUNDING INFORMATION

One Clinic provided funding for the organization of the Delphi process. Neither patients nor experts were remunerated for their participation. This research/work/investigator was supported (in part) by the Division of Intramural Research of the NIH, NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICT OF INTEREST STATEMENT

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article and its supplementary information files.

ORCID

Alba Nicolas-Boluda  <https://orcid.org/0000-0002-3029-8755>

Enora Le Roux  <https://orcid.org/0000-0002-2238-7133>

Jerome Bouaziz  <https://orcid.org/0000-0002-4674-8626>

Paolo Vercellini  <https://orcid.org/0000-0003-4195-0996>

Pamela Stratton  <https://orcid.org/0000-0002-8700-7197>

Arnaud Fauconnier  <https://orcid.org/0000-0003-0724-6831>

REFERENCES

1. Zondervan KT, Becker CM, Missmer SA. Endometriosis. *N Engl J Med*. 2020;26(382):1244-1256.
2. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. *Nat Rev Dis Primers*. 2018;4:9.

3. Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. *BMJ*. 2015;350:g7818.
4. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. *BMC Med Res Methodol*. 2010;10:22.
5. Powers JH, Patrick DL, Walton MK, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. *Value Health*. 2017;20:2-14.
6. Duffy J, Hirsch M, Vercoe M, et al. A core outcome set for future endometriosis research: an international consensus development study. *BJOG*. 2020;127:967-974.
7. Becker CM, Laufer MR, Stratton P, et al. World endometriosis research foundation endometriosis phenome and biobanking harmonisation project: I. Surgical phenotype data collection in endometriosis research. *Fertil Steril*. 2014;102:1213-1222.
8. Fassbender A, Rahmioglu N, Vitonis AF, et al. World endometriosis research foundation endometriosis phenome and biobanking harmonisation project: IV. Tissue collection, processing, and storage in endometriosis research. *Fertil Steril*. 2014;102:1244-1253.
9. Rahmioglu N, Fassbender A, Vitonis AF, et al. World endometriosis research foundation endometriosis phenome and biobanking harmonization project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. *Fertil Steril*. 2014;102:1233-1243.
10. Vitonis AF, Vincent K, Rahmioglu N, et al. World endometriosis research foundation endometriosis phenome and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. *Fertil Steril*. 2014;102:1223-1232.
11. Field J, Holmes MM, Newell D. PROMs data: can it be used to make decisions for individual patients? A narrative review. *Patient Relat Outcome Meas*. 2019;10:233-241.
12. Boukdedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. *PLoS One*. 2011;6:e20476.
13. Nicolas-Boluda A, Oppenheimer A, Bouaziz J, Fauconnier A. Patient-reported outcome measures in endometriosis. *J Clin Med*. 2021;10:5106.
14. Keckstein J, Ulrich U, Possover M, Schweppe KW. ENZIAN-Klassifikation der tief infiltrierenden endometriose. *Zentralbl Gynäkol*. 2003;125:291.
15. Keckstein J, Saridogan E, Ulrich UA, et al. The #Enzian classification: a comprehensive non-invasive and surgical description system for endometriosis. *Acta Obstet Gynecol Scand*. 2021;100:1165-1175.
16. Chapron C, Fauconnier A, Vieira M, et al. Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. *Hum Reprod*. 2003;18:157-161.
17. Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther*. 2000;26:191-208.
18. Vercellini P, Donati A, Ottolini F, et al. A stepped-care approach to symptomatic endometriosis management: a participatory research initiative. *Fertil Steril*. 2018;109:1086-1096.
19. Thirlaway K, Fallowfield L, Cuzick J. The sexual activity questionnaire: a measure of women's sexual functioning. *Qual Life Res*. 1996;5:81-90.
20. Oppenheimer A, Panel P, Rouquette A, du Cheyron J, Deffieux X, Fauconnier A. Validation of the sexual activity questionnaire in women with endometriosis. *Hum Reprod*. 2019;34:824-833.
21. Facchin F, Buggio L, Dridi D, Barbara G, Vercellini P. The subjective experience of dyspareunia in women with endometriosis: a systematic review with narrative synthesis of qualitative research. *Int J Environ Res Public Health*. 2021;18:12112.
22. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67:361-370.
23. Fauconnier A, Staraci S, Huchon C, Roman H, Panel P, Descamps P. Comparison of patient- and physician-based descriptions of symptoms of endometriosis: a qualitative study. *Hum Reprod*. 2013;28:2686-2694.
24. Jairath N, Weinstein J. The Delphi methodology (part one): a useful administrative approach. *Can J Nurs Adm*. 1994;7:29-42.
25. von der Gracht HA. Consensus measurement in Delphi studies: review and implications for future quality assurance. *Technol Forecast Soc Change*. 2012;79:1525-1536.
26. Sacristán JA, Aguarón A, Avendaño-Solá C, et al. Patient involvement in clinical research: why, when, and how. *Patient Prefer Adherence*. 2016;10:631-640.
27. Kyama CM, Mwenda JM, Machoki J, et al. Endometriosis in African women. *Womens Health (Lond)*. 2007;3:629-635.
28. Brüggmann D, Elizabeth-Martinez A, Klingelhöfer D, Quarcoo D, Jaque JM, Groneberg DA. Endometriosis and its global research architecture: an in-depth density-equalizing mapping analysis. *BMC Womens Health*. 2016;16:64.
29. Moradi M, Parker M, Sneddon A, Lopez V, Ellwood D. The endometriosis impact questionnaire (EIQ): a tool to measure the long-term impact of endometriosis on different aspects of women's lives. *BMC Womens Health*. 2019;19:64.
30. Gater A, Taylor F, Seitz C, Gerlinger C, Wichmann K, Haberland C. Development and content validation of two new patient-reported outcome measures for endometriosis: the endometriosis symptom diary (ESD) and endometriosis impact scale (EIS). *J Patient Rep Outcomes*. 2020;4:13.
31. Moos RH. The development of a menstrual distress questionnaire. *Psychosom Med*. 1968;30:853-867.
32. Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. *Health Qual Life Outcomes*. 2010;8:138.
33. Puchar A, Panel P, Oppenheimer A, Du Cheyron J, Fritel X, Fauconnier A. The ENDOPAIN 4D questionnaire: a new validated tool for assessing pain in endometriosis. *J Clin Med*. 2021;10:3216.
34. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*. 1993;4:353-365.
35. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. *Br J Surg*. 1995;82:216-222.
36. Jones G, Jenkinson C, Kennedy S. Development of the short form endometriosis health profile questionnaire: the EHP-5. *Qual Life Res*. 2004;13:695-704.
37. Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C. Development of an endometriosis quality-of-life instrument: the endometriosis health Profile-30. *Obstet Gynecol*. 2001;98:258-264.
38. Chapron C, Dubuisson JB, Pansini V, et al. Routine clinical examination is not sufficient for diagnosing and locating deeply infiltrating endometriosis. *J Am Assoc Gynecol Laparosc*. 2002;9:115-119.
39. Dragisic KG, Padilla LA, Milad MP. The accuracy of the rectovaginal examination in detecting cul-de-sac disease in patients under general anaesthesia. *Hum Reprod*. 2003;18:1712-1715.
40. Aredo JV, Heyrana KJ, Karp BI, Shah JP, Stratton P. Relating chronic pelvic pain and endometriosis to signs of sensitization and myofascial pain and dysfunction. *Semin Reprod Med*. 2017;35:88-97.

41. Thomassin-Naggara I, Lamrabet S, Crestani A, et al. Magnetic resonance imaging classification of deep pelvic endometriosis: description and impact on surgical management. *Hum Reprod.* 2020;35:1589-1600.
42. Indrielle-Kelly T, Frühauf F, Fanta M, et al. Diagnostic accuracy of ultrasound and MRI in the mapping of deep pelvic endometriosis using the international deep endometriosis analysis (IDEA) consensus. *Biomed Res Int.* 2020;2020:3583989.
43. Guerriero S, Condous G, van den Bosch T, et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. *Ultrasound Obstet Gynecol.* 2016;48:318-332.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Nicolas-Boluda A, Le Roux E, Tavenet A, et al. Developing a set of patient-centered outcomes for routine use in endometriosis: An international Delphi study. *Acta Obstet Gynecol Scand.* 2024;103:138-152. doi:[10.1111/aogs.14694](https://doi.org/10.1111/aogs.14694)